CD4 and colitis: Overall, these data show that mice exposed to TNBS colitis after human CD4 T cell replenishment and concomitantly treated with FANA-CD39-AS oligonucleotides display a more benign course of colitis while showing a more immunoregulatory phenotype in peripheral blood and spleen and—to a lesser extent—IEL-derived CD4 cells.